GSK renews USD250M manufacturing deal with Bora Pharmaceuticals through 2030

CANADA—British drugmaker GSK has renewed its manufacturing partnership with Bora Pharmaceuticals, signing a USD 250 million agreement that extends their collaboration through 2030.

The five-year contract reinforces a productive working relationship that has developed between the two companies over nearly a decade.

Under the renewed agreement, Bora will provide end-to-end manufacturing services for more than 20 commercial GSK product lines.

The scope encompasses over 335 individual products targeting various conditions, including HIV, malaria, pneumonia, parasitic infections, depression, migraine, acne, eczema, and psoriasis.

Canadian facility takes center stage

The bulk of the manufacturing work will take place at Bora’s facility in Mississauga, Ontario.

GSK currently represents the largest pharmaceutical partner operating at this site, according to the contract development and manufacturing organization (CDMO).

The agreement also grants GSK access to additional facilities within Bora’s network, including a new oral solid-dose plant in Minnesota.

The Mississauga connection runs deep between the two companies.

Bora acquired the 170,000-square-foot facility from GSK in 2020, creating a foundation for their ongoing partnership.

Since taking ownership, Bora has invested heavily in flexible manufacturing technology, transforming the site into what the company describes as a strategic hub for leading global pharmaceutical companies.

Facility capabilities and growth

The Ontario plant has experienced significant expansion under Bora’s stewardship.

It now serves 32 clients, supports 61 products, and has completed more than 400 project and development batches.

The facility offers manufacturing, processing, and commercialization services for both prescription and over-the-counter products, handling oral solid-dose medications, liquids, and semi-solid therapeutics.

Equipped with 18 highly configurable manufacturing modules, the site provides packaging capabilities for tablets, capsules, nasal sprays, and creams.

This versatility allows Bora to maintain an uninterrupted supply of key GSK medicines while leveraging experienced development teams across its global infrastructure.

Shared vision for quality and reliability

Bobby Sheng, Bora’s CEO, emphasized the partnership’s foundation in mutual trust and quality commitment.

“From day one, this partnership was built on mutual trust and a shared commitment to quality,” he stated.

“Reaching nearly a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability.”

Bora’s North American presence extends beyond Canada.

The company operates facilities in Baltimore, Maryland, and Maple Grove, Minnesota, alongside four manufacturing sites in Taiwan.

The CDMO acquired its Baltimore sterile manufacturing facility through a 2024 agreement with Emergent BioSolutions, while the Minnesota site came through its USD 210 million Upsher-Smith acquisition in 2024.